IN THIS ISSUE

Highlight research articles ......................... 1111

NEWS IN BRIEF

Important news stories affecting the community .......... 1114

NEWS IN DEPTH

Shelved 4-1BB Antibodies Make Comeback ............ 1118

RESEARCH BRIEFS

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer .......... 1137
P.A. Konstantinopoulos, R. Ceccaldi, G.L. Shapiro, and A.D. D’Andrea

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib .......... 1155

Précis: Clinically observed in-frame tandem duplication of the EGFR kinase domain is a recurrent oncogenic driver alteration in NSCLC and confers sensitivity to EGFR inhibitors.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets .......... 1164

Précis: Sequencing of matched primary tumors and brain metastases reveals branched evolution and frequent oncogenic alterations in potentially targetable pathways.

In Focus

All the World’s a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health .......... 1133
Précis: Loss of NF2 promotes thyroid tumorigenesis by increasing expression of both wild-type and mutant RAS in a YAP-dependent manner, resulting in enhanced dependency on MAPK signaling.

See commentary, p. 1127

AC icon indicates Author Choice
For more information please visit http://www.aacrjournals.org

Garcia-­Rendueles, Ricarte-­Filho, and colleagues found that chr22q LOH is a common event in poorly differentiated thyroid cancer (PDTC) and is preferentially associated with RAS mutations. In mice, neither thyroid-specific activation of Hras nor NF2 deletion was sufficient for transformation, but their combined disruption led to highly penetrant PDTC characterized by increased MAPK signaling. Inactivation of the Hippo pathway in NF2-­deficient cells increased YAP-­mediated transcription of wild-type and mutant RAS isoforms, whereas disruption of YAP-­TEAD binding blocked RAS transcription and inhibited cancer cell growth. Additionally, NF2 loss sensitized RAS-­mutant thyroid cancer cells to MEK inhibitors. These results identify YAP as a critical effector of RAS-­induced tumorigenesis and suggest that inhibition of YAP or MEK may be effective in RAS-­driven thyroid cancer. For details, please see the article by Garcia-­Rendueles, Ricarte-­Filho, and colleagues on page 1178.
CANCER DISCOVERY

5 (11)


Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/5/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/5/11.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.